ROVI cuts 2026 revenue guidance on lower pharma demand

ROVI cut full-year 2026 operating revenue guidance to low- to mid-single-digit growth from high single digits to low double digits, citing weaker partner demand and pricing pressure in heparin. Q1 operating revenue fell 1.5% to €152.5 million and EBITDA dropped 33% to €20.3 million, with margin down to 13.3% from 19.6%. Gross margin improved to 62.3%, and the company said it will launch two new multinational Risperidone QUAR studies with enrollment expected by Q4 2026.

Analysis

This is less a broad operational setback than a margin reset disguised as a growth downgrade. The key signal is that ROVI’s earnings mix is deteriorating just as it is leaning harder on higher-value manufacturing and specialty pharma to stabilize the top line; that makes the stock more sensitive to execution slippage than the headline revenue range suggests. The Phoenix asset arriving late also matters because it delays the conversion of announced capacity into visible revenue, keeping fixed-cost absorption weaker for longer.

The main second-order effect is competitive, not just company-specific: partner destocking and pricing pressure in heparin imply the market is normalizing after a period of oversupply, which should benefit lower-cost producers and diversified CMOs with less exposure to a single molecule. Meanwhile, Okedi growth is still meaningful, but at this stage the market will start demanding evidence of durable European rollout economics rather than launch momentum alone. If the new multinational studies for Risperidone QUAR land well, they can re-rate the pipeline; if not, ROVI risks being valued on a slower-growth, lower-margin base business for the next 6-9 months.

The contrarian angle is that the gross margin improvement may be more fragile than it looks because it was helped by items that are not fully repeatable, while SG&A and R&D are stepping up ahead of clinical spend and Phoenix integration. That creates a near-term trap: reported margin could look supported even as underlying cash earnings compress. The market is likely underestimating how much of the FY26 debate will hinge on partner inventory normalization versus true end-demand recovery, which makes the next two quarters more important than the full-year guide.

Key Decisions for Investors

• Short ROVI on any post-earnings bounce or into strength over the next 2-4 weeks; use a tight stop above the pre-guidance range as the stock likely needs at least one more quarter of data to de-risk margin compression.
• Pair trade: long a diversified CDMO/CMO peer basket against short ROVI for 3-6 months; thesis is that ROVI has higher single-product and partner-concentration risk while peers with broader utilization should show cleaner margin resilience.
• If you want optionality on pipeline upside, consider a small call spread on ROVI 6-9 months out, funded by stock or put premium, because Risperidone QUAR readouts are a binary catalyst but still too early for outright directional conviction.
• Avoid adding ahead of the next quarterly print unless there is evidence of heparin destocking reversal; the better entry is after either stabilization in low molecular weight heparin or confirmation that Phoenix can offset the margin drag.